D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases as well as application of big data in CNS drug research and diagnostics. D&D Pharmatech is the parent company of U.S.-based Neuraly, Precision Molecular, Valted Seq, Theraly Fibrosis and P4 Microbiome.
Therapeutic Focus
Building a global biotech company
D&D runs global product development operations via multiple partnerships and owns subsidiaries focused on specific therapeutic areas. D&D is a technology and financial holding company that operates at two research and development sites: Korea (Pangyo) and U.S. (Gaithersburg, MD).
D&D Pharmatech was founded in 2014 in Korea and expanded to the U.S. through research and development collaborations with multiple scientific co-founders from academia and industry.
DD01
Severe Obesity & NASH
GLP1R /GCGR agonist
TLY012
NASH-Liver Fibrosis
DR5 agonist
TLY012
Chronic Pancreatitis
DR5 agonist
TLY012
Systemic Sclerosis
DR5 agonist
PMI03
Neuroinflammation
sEH targeting PET Tracer
PMI04
Neuroinflammation
CSF1R targeting PET/SPECT Tracer
PMI05
Oncology
CAIX targeting PET/SPECT Tracer
PMI06
Oncology
PD-L1 targeting PET Tracer
Yoo Seok Hong, MBA
Chief Executive Officer, D&D Pharmatech
Seulki Lee, PhD
Founder, Chairman, Chief Executive Officer, D&D Pharmatech
Viktor Roschke, PhD
Chief Scientific Officer, D&D Pharmatech, Neuraly and Theraly Fibrosis
Sunghoon Hong, KICPA
Chief Financial Officer, D&D Pharmatech
Soobong Park, PhD
Chief Technical Officer, D&D Pharmatech
Sungmook Lim, PhD
Founder, R&D Executive Director, D&D Pharmatech
Martin G. Pomper, MD, PhD
Founder and interim Chief Scientific Officer, Precision Molecular
Valina L. Dawson, PhD
Founder and Chief Executive Officer, Valted Seq
Ted M. Dawson, MD, PhD
Founder and Chief Scientific Officer, Valted Seq
Kang Choon Lee, PhD
Founder, D&D Pharmatech
Anna Nesterenko, CPA
Director
Accounting and Finance
Neuraly
Adam Bell, PhD
Vice President
Translational Medicine
and Regulatory Affairs
Neuraly
Barbara Rempe, SHRM-CP
Human Resource Manager Neuraly
Celia Baula, PMP, MBA
Senior Director
R&D Program Management Neuraly
Daniel Lee, MS
Executive Director
Clinical Affairs
Neuraly
Don Ho, PhD
Director
Intellectual Property Neuraly
Dong Ik Lee, PhD
Principal Scientist
Drug Discovery
Neuraly
Isabell Loftin, PhD
Vice President
Diagnostics
Valted Seq
JinSik Kim, CPA
Director
Accounting and Finance
D&D Pharmatech
Joshua Yang, MS
Head
Business Development
D&D Pharmatech
Mohammad N Ranjbar, PhD
Senior Director
Bioinformatics
Valted Seq
Nayoung Louie, PhD
Director
Strategy
Neuraly
Nina Urban, MS, MBA
Vice President
Alliance Management
Neuraly
Okcheol Jeon, PhD
Principal Scientist
Drug Discovery
D&D Pharmatech
Pankaj J.
Pasricha, MD
Clinical Advisor
P4 Microbiome
Philip Phan, PhD
Strategic Advisor
P4 Microbiome
Pyung Ah Park
Internal Auditor/Legal Counsel
D&D Pharmatech
Sheri Fan, CPA
Director
R&D Program Management and Budget Oversight.
Neuraly
Svetlana Sosnovtseva, MS
Senior Director
Assay Development
Neuraly
Yen Lin, PhD
Vice President
CMC
Neuraly
D&D’s commitment to science and cutting-edge research is reflected in our track record of publications. A few recent examples of high impact and high-quality publications co-authored by D&D scientific co-founders and scientists related to our products.
APR 20, 2022
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with PD
APR 18, 2022
JAN 29, 2022
HOW THE PRISM PARKINSON’S RESEARCH STUDY MIGHT CHANGE THE WAY WE TREAT PARKINSON’S
https://davisphinneyfoundation.org/prism-parkinsons-research-study/
JAN 28, 2022
JAN 06, 2022
디앤디파마텍 DD01, 美화학학회 전문 매체에 성공적 제조품질관리 협업 사례로 소개
https://connect.acspubs.org/WuXiSTA_CDMOPartner?partnerref=CENonline
APR 22, 2022
MAR 31, 2022
MAR 16, 2022
DEC 17, 2021
NOV 04, 2021
D&D Pharmatech (Korea)
5th Floor, I&C Building, 24, Pangyo-ro 255 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, (13486) Rep. of Korea
Tel : +82-31-8019-7771
Fax : +82-31-8019-7772
E-mail : info@ddpharmatech.com
D&D Pharmatech / Neuraly, Inc (US)
704 Quince Orchard Road, Suite 320
Gaithersburg, MD 20878
E-mail : info@neuralymed.com